$46.53−0.50 (−1.06%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Alkermes (ALKS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 5.2% in FY25, net margin 16.4%, and free cash flow (~$480.3M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▼5.2%
1,475.9
FY21→FY25CAGR +5.9%/yr
Net income ($M)▼34.2%
241.7
one-off year: see footnoteCAGR —
Free cash flow ($M)▲18.4%
480.3
FY21→FY25CAGR +59.8%/yr
Diluted EPS▼34.1%
1.43
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+2.4%
164.8mn → 168.7mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$40.4M
+20.7% YoY in FY25 · 2.7% of revenue.
Returns vs FCF
0%
$0.0M returned vs $480.3M of FCF in FY25. Buybacks covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
16¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 83.2% → 86.7%. Net margin 16.4% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,753,599.0 | 1,475,899.0 | 1,557,632.0 | 1,663,405.0 | 1,111,795.0 | 1,173,751.0 | ▼5.2% | +5.9% |
Cost of revenue | 300,119.0 | 196,457.0 | 245,331.0 | 253,037.0 | 218,068.0 | 197,323.0 | ▼19.9% | −0.1% |
Gross profit | 1,453,480.0 | 1,279,442.0 | 1,312,301.0 | 1,410,368.0 | 893,727.0 | 976,428.0 | ▼2.5% | +7.0% |
Research & development | 430,423.0 | 323,964.0 | 245,326.0 | 270,806.0 | 272,702.0 | 290,924.0 | ▲32.1% | +2.7% |
Selling, general & admin | 877,916.0 | 701,522.0 | 645,238.0 | 689,751.0 | 590,751.0 | 549,610.0 | ▲8.7% | +6.3% |
Total operating expenses | 1,389,279.0 | 1,025,486.0 | 891,665.0 | 996,246.0 | 899,816.0 | 878,682.0 | ▲15.0% | +3.9% |
Operating incomefeeds ROC rank | 64,201.0 | 253,956.0 | 420,636.0 | 414,122.0 | −6,089.0 | 97,746.0 | ▼39.6% | +27.0% |
Other income, net | −52,889.0 | 37,494.0 | 23,114.0 | 7,397.0 | −25,039.0 | −10,019.0 | — | — |
Pretax income | 11,312.0 | 291,450.0 | 443,750.0 | 421,519.0 | −31,128.0 | 87,727.0 | ▼34.3% | +35.0% |
Income tax | 11,663.0 | 49,786.0 | 71,612.0 | −97,638.0 | 2,024.0 | 11,326.0 | ▼30.5% | +44.8% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | −351.0 | 241,664.0 | 367,070.0 | 355,757.0 | −158,267.0 | −48,169.0 | ▼34.2% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.02 | 1.43 | 2.17 | 2.10 | −0.97 | −0.29 | ▼34.1% | — |
Diluted shares (mn) | 176.37 | 168.74 | 169.20 | 169.73 | 163.74 | 164.75 | ▼0.3% | +0.6% |
| Margins | ||||||||
Gross margin77th pct in Healthcare | 82.9% | 86.7% | 84.2% | 84.8% | 80.4% | 83.2% | ▲2.4pp | +3.5pp |
Operating margin | 3.7% | 17.2% | 27.0% | 24.9% | −0.5% | 8.3% | ▼9.8pp | +8.9pp |
Net margin39th pct in Healthcare | −0.0% | 16.4% | 23.6% | 21.4% | −14.2% | −4.1% | ▼7.2pp | +20.5pp |
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was −7% vs a 13% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was −23% vs a 13% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 10 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Alkermes' revenue last fiscal year?
Alkermes reported revenue of $1,475.9M in fiscal 2025, down 5.2% from fiscal 2024.
What was Alkermes' net income?
Alkermes reported net income of $241.7M in fiscal 2025, a net margin of 16.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

